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Abstract
Inflammatory bowel disease (IBD) is characterized by two partially distinct alimentary
disease processes, namely Crohn’s disease (CD) and ulcerative colitis (UC), affecting
genetically predisposed individuals. CD and UC were first described in 1932 and 1859,
respectively. It is estimated that 1.5 million in North America and 2.5 million persons in
Europe have IBD. The peak incidence of CD and UC is between 20–30 years and 30–40
years of age, respectively. Both incidence and prevalence of CD and UC are similar
across males and females. However, several studies suggest a female predominance in
CD and a male predominance in UC. The pathogenesis of  IBD is  attributed to an
uncontrolled immune-mediated inflammatory response to an unrecognized environ-
mental  trigger that  interacts with the intestinal  flora.  Various determinants of  IBD
include the following: peculiar environmental triggers, intestinal immune mechanisms,
heritable factors, gut flora, diet, mesenteric fat, medications, nicotine, infectious agents,
immunization, hygiene,  pregnancy,  breastfeeding, stress and lifestyle.  Predominant
complications  in  IBD  are  surgery,  malnutrition,  disease  exacerbations  and  cancer.
Patients with CD have a higher mortality compared to general population. Epidemio-
logical studies continue to expand our understanding of the distribution, determinants
and mechanisms of IBD. This has enabled us to recognize safer and effective approaches
to management.
Keywords: inflammatory bowel disease, Crohn’s disease, ulcerative colitis, epidemiol-
ogy, incidence, prevalence
1. Introduction
Inflammatory bowel disease (IBD) is  an idiopathic chronic inflammatory disorder of  the
alimentary tract that encompasses two major closely related yet heterogeneously distinct
disease entities—Crohn’s disease (CD) and ulcerative colitis (UC). IBD is characterized by
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chronic  or  relapsing  uncontrolled  immune  activation  and  inflammation  in  genetically
predisposed individuals to a yet unknown environmental trigger that interacts with the gut
flora and primarily affects the digestive tract [1–7]. Historically, Dr. Burrill Crohn, Dr. Leon
Ginzburg and Dr. Gordon Oppenheimer first described CD in 1932 as regional or terminal
ileitis—inflammation of terminal ileum [8–10]. In 1859, Dr. Samuel Wilks recognized UC as
a discrete entity,  but it  was Sir  Arthur Hurst,  who described its  endoscopic pattern and
distinguished it from the more common bacillary dysentery [8, 9, 11]. Pathologically, CD
usually consists of transmural inflammation (all  layers from mucosa to serosa) and may
discontinuously involve any part of the alimentary tract from mouth to anus, whereas UC is
characterized by submucosal inflammation limited to the colon [6]. Approximately, one and
a half million residents in the USA and two and a half million in Europe have IBD, with about
half represented in each of the two discrete IBD subgroups [2, 12].
2. Incidence, prevalence and distribution
Though now recognized worldwide, traditionally IBD was considered a condition that pri-
marily affected Caucasians across Europe, North America and Australia [1]. Hence, most of
the available epidemiologic data on CD and UC have been derived from population-based
studies conducted in these geographic regions [1]. The incidence and prevalence of CD and
UC have stabilized in the aforementioned regions; however, it is still higher than in the rest
of the world [1]. Further, the incidence and prevalence of IBD, predominantly CD, have
increased in the developing world particularly in the Middle East, Southeast Asia and the
Asia Pacific Region [7, 12, 13]. Meanwhile, South America and Africa have significantly low
incidence and prevalence rates, albeit anecdotal reports have hinted an increase in inci-
dence [14, 15].
Even in the West, IBD has become increasingly recognized among minority populations [1].
The most significant rise in incidence has occurred in second-generation immigrants from
low-risk geographic regions to Western countries, that is, high-risk regions. This supports
the concept of an equal if not higher contribution from environmental influences compared
to genetic predisposition [1, 16]. Also, has been noted a higher incidence of IBD among
immigrants and their families who migrated from socioeconomically backward regions [1].
Moreover, compared to minorities in the West, recent immigrants tend to have a milder
disease course [1].
Globally, there remains a paucity of accurate epidemiologic data due to clinical overlap of the
IBD entities with conditions such as infectious colitis and differences in the health care systems
precluding reliable case estimation. The recognized IBD cases may further only represent a
fraction of the actual disease burden due to diagnosis requiring invasive and expensive
modalities. Moreover, at times, CD cannot be clearly distinguished from UC, especially early
in the disease course before distinctive characteristics have manifested, often requiring
reassignment of the IBD subgroup diagnosis [17]. Despite the aforementioned limitations, the
incidence and prevalence of both CD and UC have demonstrated a distribution trend. The
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incidence and prevalence data vary across the globe depending upon geographic region,
environment, immigration trends, ethnicity [1–3] and even differ within the same geographic
region. Moreover, a north-south distribution gradient has been observed for IBD risk across
the world [18]. This has been attributed to regional differences in sunlight and vitamin D
exposure with high levels of exposure inversely correlated with risk of IBD [19, 20].
The annual incidence rates of CD are comparable across most of the developed world. It is
estimated to be 20.2 per 100,000 person-years, 12.7 per 100,000 person-years, 29.3 per 100,000
person-years and 16.5 per 100,000 person-years in North America, Europe, Australia and New
Zealand, respectively [21–23]. In contrast, Asia has a low incidence rate of approximately 0.54
per 100,000 person-years [24]. Similarly, the incidence rates for UC in North America, Europe
and Asia range from 7.6 to 19.5 per 100,000 person-years, 1.7 to 13.6 per 100,000 person-years
and 0.3 to 5.8 per 100,000 person-years, respectively [4]. In the past, UC was considered to be
slightly more prevalent; however, an increased incidence of CD in the past few decades has
resulted in a trend reversal. Most recent estimates of prevalence of CD in North America are
25–300 per 100,000 person-years and that for UC are 170–250 and 43–294 per 100,000 person-
years, respectively, in North America and Europe [21, 25, 26]. Overall, both the incidence and
prevalence of CD and UC are increasing with time. This can be attributed to a number of factors
including improved sanitation, diet and medication exposures, increased IBD awareness
among patients and clinicians, use of improved endoscopic and radiologic diagnostic modal-
ities and widened health care access [21, 27].
2.1. Age and gender disparity
Although IBD can occur at any age, the peak age of onset for CD and UC is generally between
20–30 years and 30–40 years of age, respectively [1, 4, 6, 21]. However, some European cohorts
have suggested a second peak between 60–70 years of age, especially for UC. The most
plausible explanation for this additional peak is ascertainment bias due to increased health
care access and more frequent evaluation of older patients. Majority of North American
population-based study has shown that the median and mean age of diagnosis of CD and UC
range between 30–45 years and 40–45 years, respectively [28, 29]. Additionally, these studies
especially in adults have suggested a female predominance in CD and male predominance in
UC [1, 30]. This gender-based disparity may be attributed to hormonal or life-style factors.
However, the variation is inconsistent, particularly in low IBD incidence regions, where CD
may be more prevalent among men [25, 31]. Men tend to be diagnosed with IBD, especially
UC at a later age than their female counterparts [6]. On the other hand, in the pediatric
population, the trend in gender distribution is reversed with more boys having CD than girls
[32].
2.2. Racial and ethnic disparity
There appears to be a marked ethnic and racial variation in the incidence of IBD. Early studies
from the 1960s reported a lower incidence of IBD, specifically UC among African-Americans
[33]. However, these studies were conducted in regions with predominant white populations,
and more recent studies from 1990s have challenged these findings with comparable incidence
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rates among Whites and non-Whites [34, 35]. Further, CD was proposed to be more aggressive
with earlier age of onset in African-Americans. A recent systematic review, however, suggested
that the variance in IBD severity extrapolates from socioeconomic inequalities such as health
care affordability and accessibility, rather than inherent biologic or genetic dissimilarities [36,
37]. Ethnically, the Jews in particular are vulnerable to develop IBD, with incidence rates being
several fold higher than in the general population across the globe. Further, IBD is more
common among the Ashkenazi Jews than the Sephardic Jews in the Middle East, but this trend
is reversed in the United States and northern Europe, indicating influence of environmental
factors [38].
3. Pathogenesis and risk factors
Pathogenically, IBD is believed to be due to uncontrolled immune activation and inflammation
of the alimentary tract in genetically predisposed individuals. It is triggered by the interaction
of an unknown environmental agent with the autoantigens believed to reside on nonpatho-
genic commensal bacteria of the intestinal microbiota (Figure 1) [7]. The primary mechanism
of inflammatory insult in IBD is immune mediated. Intestinal epithelial cells in active IBD
express HLA class II molecules that activate macrophages to secrete pro-inflammatory
cytokines (IL-1, IL-6, IL-8, and TNF-α) and suppress the downregulatory cytokines (IL-2, IL-10,
and TGF-β) in the lamina propria, thereby fostering chronic inflammation [5, 7, 12].
Figure 1. Factors implicated in the etiopathogenesis of IBD.
Various environmental triggers have been attributed to IBD causation. They include external
antigens such as infectious pathogens (bacteria and viruses), dietary agents and autoantigens
residing on the microbial gut flora [1, 6, 12]. In addition, both CD and UC tend to have genetic
predisposition in about 15% cases. In regard to first-degree relative for CD and UC, the lifetime
risk of developing IBD is approximately 5 and 2% among non-Jewish populations and 8 and
5% among Jewish populations, respectively [39]. The genetic predisposition is stronger for CD
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than UC based on higher concordance rates (50 and 10% vs. 16 and 4%) among monozygotic
and dizygotic twins, respectively [40, 41].
Dietary factors more pronounced in typical western diet have been implicated in the patho-
genesis of IBD. Comprehensive review of studies involving patients with CD has suggested
possible association between increased consumption of refined sugars and animal meat and
risk of development of IBD [42, 43]. The aforementioned dietary components are believed to
interact with intestinal flora and produce pro-inflammatory agents [44]. Individuals who
consume less dietary fiber, raw fruits and vegetables tend to have higher predilection for IBD
[44]. Meanwhile, molecular studies have linked adipose tissue to intestinal inflammation [45,
46]. However, it remains unclear if this translates into a causal or clinically meaningful
association between obesity and CD. Regardless, obese patients with CD tend to have a rapid
disease progression compared to their underweight counterparts [47, 48]. Moreover, sedentary
lifestyle is associated with overall higher IBD incidence [49].
Among environmental factors, smoking has a pivotal role in IBD with divergent effects in UC
and CD [1]. Both current as well as former smoking, including exposure to passive smoking
during childhood, is associated with twofold increase in the risk of CD [50, 51]. Smokers with
CD tend to have an earlier age of onset, more aggressive (stricturing or penetrating) disease
phenotype, heightened need for steroids and immunosuppressants and overall more surgical
interventions as well as higher risk of postresection recurrence [52, 53]. In contrast to CD,
smoking safeguards against UC and even indeterminate colitis, with an estimated 50% risk
reduction in current smokers. However, this protective effect is less pronounced in females.
Further, smokers with UC tend to have milder disease course, with less frequent proximal
extension of disease and decreased need for immunosuppression and surgery [53, 54].
The precise mechanisms driving these contrasting effects of smoking on the two IBD subtypes
remain unclear. It is hypothesized that smoking causes polymorphisms in genes regulating
nicotine metabolism and decreases heat shock protein-70 resulting in reduced protection
against cellular oxidative stress, which in turn impairs endothelial function in the intestinal
mucosal barrier and promotes inflammation [55–58]. On the other hand, it is proposed that
smoking alters the gut flora to reduce predisposition to UC [59].
Recent studies have suggested that infectious agents, such as Salmonella and Campylobacter,
impart heightened risk for IBD development [60], while Clostridium difficile and cytomegalo-
virus have been linked with IBD exacerbations [61, 62]. However, no definite causal association
has been identified.
Meanwhile, poor hygienic conditions, including large family size, lack of access to running
water, consumption of unpasteurized milk, early exposure to farm animals and pets, have been
suggested to protect against IBD development [1, 30, 63–65]. However, these associations are
derived from studies conducted in the West and they failed to be replicated in the developing
world [1, 66]. On the other hand, there is no definite association between immunization and
risk of IBD. Early studies have linked attenuated live measles virus vaccine with IBD occur-
rence; however, recent studies support the contrary thereby suggesting a protective role [67].
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Several pharmacologic agents have also been implicated as potential risk factors for IBD. They
include NSAIDs, oral contraceptives, hormonal replacement therapy and antibiotics [68–73].
On the contrary, studies suggesting role of nutritional factors such as vitamin D in IBD
development remain equivocal [1].
With regards to pregnancy, there is no definite association between the mode of childbirth
(caesarian vs. vaginal delivery) and risk of IBD [74]. However, breastfeeding may play a
protective role against IBD development later in life [1]. Meanwhile, depression and anxiety
have not only been linked to higher risk of development of IBD but also to increased disease
severity, need for surgical intervention, reduced quality of life and diminished response to
immunosuppresants [75].
4. Classification
The heterogeneity of demographic, anatomic and disease behavior characteristics in IBD
warranted a systematic grouping scheme to place its various phenotypes into simple catego-
ries. The first attempt was made by the Working Party of the World Congress of Gastroenter-
ology that met in Vienna in 1998. Their report known as the “Vienna Classification” was
published in the Journal of Inflammatory Bowel Diseases in 2000. This classification attempted
to stratify CD into 24 disease clusters based on age at diagnosis, disease location and disease
behavior (Table 1) [76]. Subsequently, the Vienna classification was critiqued owing to lack of
universal clinical applicability [77].
Vienna classification Montreal classification
Age at diagnosis A1: Below 40 years A1 Below 16 years
A2: Above 40 years A2 Between 17 and 40 years
A3 Above 40 years
Location L1 Ileal L1 Ileal
L2 Colonic L2 Colonic
L3 Ileocolonic L3 Ileocolonic
L4 Upper L4 Upper disease modifier or isolated upper disease
Behavior B1 Nonstricturing, nonpenetrating B1 Nonstricturing, Nonpenetrating
B2 Stricturing B2 Stricturing
B3 Penetrating B3 Penetrating
p Perianal disease modifier
Table 1. Vienna and Montreal classification of Crohn’s disease.
The Working Party of the Montreal World Congress of Gastroenterology then met in 2005 and
put forth the Montreal classification of IBD (Tables 1 and 2) [78]. This new scheme grouped
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CD primarily based on the same variables proposed by the experts at Vienna including
patient’s age at diagnosis (A1, 16 years and younger; A2, 17–40 years; A3, >40 years), disease
location (L1, ileal: L2, colonic; L3, ileocolonic) and disease behavior (B1, nonstricturing,
nonpenetrating; B2, stricturing; B3, penetrating). In addition, it introduced modifiers for upper
tract disease location (L4) and for perianal disease (p). Further, it extended the classification to
stratify UC based on the extent and severity of the disease (Table 2) [78].
Class Extent Description
E1 Ulcerative proctitis Proximal extent of inflammation distal to rectosigmoid junction
E2 Left-sided UC (distal UC) Involvement limited to proportion of colorectum distal to the splenic
E3 Extensive UC (pancolitis) Involvement extending proximal to splenic flexure
Table 2. Montreal classification of ulcerative colitis.
5. Disease course
Based on phenotype by location, of all patients with CD at the time of diagnosis, one-third of
patients have ileal involvement, one-third of patients have colonic involvement and the rest
have ileocolonic disease. While with regard to disease behavior, 80% of all patients with CD
at the time of diagnosis have nonpenetrating/nonstricturing disease with the remaining 20%
having stricturing or penetrating disease [79]. As CD evolves, of all with nonpenetrating/
nonstricturing disease, up to one-third of patients progress to penetrating or stricturing
complications at 5 years and about half at 20 years from diagnosis [79]. Further, in terms of
disease activity, based on data from prebiologic era, about two-thirds of patients with CD tend
to have a remitting and risk of CD relapsing course one-fifth remain active and about 13% enter
long-term remission [80].
Meanwhile, for UC at the time of diagnosis, one-third of patients tend to have colonic involve-
ment distal to rectosigmoid junction, one-third up to splenic flexure, while the remaining third
have pancolitis, that is, contiguous involvement extending proximal to the splenic flexure [2].
The disease behavior is variable; 50% of UC patients with proctitis/proctosigmoiditis progress
to extensive disease at 25 years [81]. While in regard to disease activity, based on data from
prebiologic era, 57% of patients with UC tend to have a remitting and relapsing course, one
quarter go into long-term remission, and about one-fifth remain active [39, 82].
6. IBD and morbidity
The key factors driving morbidity overlap between the two IBD subgroups—CD and UC. The
predominant causes of morbidity in patients with CD are need for surgery, malnutrition
followed by disease exacerbations and cancer [2, 4]. While among patients with UC, the major
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burden of morbidity is due to the development of cancer followed by requirement for surgery
and disease exacerbations [2, 4]. Overall, surgery remains the most common cause of morbidity
in CD and a significant cause of morbidity in UC. Recently, the cumulative risk of IBD,
particularly patients with CD requiring surgery has significantly decreased with rates of
surgery being approximately 10–14% and 18–35% after 1 and 5 years, respectively [83–88]. This
is attributed to adoption of more aggressive medical therapy in recent times [1, 2, 83, 84, 89,
90]. Based on age, location and behavior of CD, the greatest need for surgery is with ileocecal
location and stricturing or penetrating/fistulizing disease phenotype [2, 86, 87]. Similarly, in
UC, the likelihood of need for colectomy has decreased recently with estimated rates of 6 and
10% after 1 and 5 years, respectively [83, 91–93]. The highest probability of colectomy is in
those with relatively recent diagnosis and severe disease especially pancolitis [2].
An interesting association has been observed between appendectomy and IBD [1]. While
appendectomy is found to protect against future occurrence of UC, it may lead to an increased
incidence of CD [94–96].
With regard to cancer as one of the drivers of morbidity, the overall risk of colorectal cancer is
significantly higher in patients with IBD compared to the general population. The primary
factors influencing this risk include persistent active inflammation, immunosuppression, long-
standing disease, extensive disease, young age at diagnosis, family history of colorectal cancer
and coexisting primary sclerosing cholangitis [2, 97]. Overall, patients with IBD have height-
ened risk of extraintestinal cancers such as lymphoproliferative and skin cancers [2, 98–100].
7. IBD and mortality
Whether or not having IBD confers a higher mortality remains debated. Population-based
studies from 1980s to 1990s suggested a moderate increase in mortality rate in CD [101, 102].
However, recent European studies have failed to replicate these findings and indicate a
comparable mortality rate in CD to the general population [103–105]. Major causes of mortality
in CD include direct, such as surgical complications and malnourishment, and indirect related
to smoking [101, 106–107].
Similarly, there is lack of definitive evidence to support higher mortality rate in patients
with UC [105, 107–110]. However, unlike CD, most deaths in UC are due to colorectal cancer
than from surgical or other complications [106, 109].
8. Conclusion
In conclusion, IBD is a condition with a unique etiopathogenesis and significant epidemiologic
burden. To the present day, epidemiological studies continue to expand our understanding of
the distribution, determinants and mechanisms of IBD. This has enabled us to recognize safer
and more effective approaches to management and therapeutics outside of mere immuno-
suppression for IBD with emphasis on prevention, preemption and immunomodulation.
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